Sign up
Pharma Capital

NetScientific portfolio company Vortex Biosciences appoints new chief executive officer

NetScientific said Bob Englert, who is currently chief technology officer, takes up the position with immediate effect, replacing Gene Walther
agreement
Vortex has also appointed Steve Crouse, who has been chief commercial officer since March 2016, to the position of chief operating officer

NetScientific PLC (LON:NSCI) has announced that its portfolio company Vortex Biosciences has appointed Bob Englert as new chief executive officer.

The healthcare IP commercialisation group said Bob Englert, who is currently chief technology officer, takes up the position with immediate effect, replacing Gene Walther, who has resigned to pursue other interests.

READ: NetScientific portfolio company ProAxsis receives grant by Invest North Ireland

The company said Bob Englert, who has been chief technology officer of Vortex since 2016, has over 25 years of global experience in medical devices and life sciences, with a particular focus on IVD, Point of Care, digital health solutions.

Vortex has also appointed Steve Crouse, who has been chief commercial officer since March 2016, to the position of chief operating officer. He will work closely with Bob Englert and the board to drive R&D and commercialisation strategies.

François R. Martelet, CEO of NetScientific and chairman of Vortex Biosciences, said: “Vortex is approaching a critical commercialisation phase with its unique CTC isolation technology, and Bob is in a unique position to drive this forward.”

He added: “With expertise gained from his role as chief technology officer and underpinned by years of industry experience, particularly in the diagnostics field, we believe he is the right person to take Vortex through the next phase of its growth.”

View full NSCI profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.